Arrowhead Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to ...
Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback